Magnesium Glycinate vs
Citrate vs Oxide — which
form actually absorbs?

Why the form of magnesium decides whether your supplement does anything at all

Magnesium on a supplement label is never just “magnesium.” It is always bonded to something else — an oxide, a citric acid molecule, or an amino acid like glycine. That bonding partner is what the form name refers to, and it controls two things that matter far more than the number on the front of the bottle: how much of the magnesium your intestine can actually absorb, and how your gut tolerates the dose.

Magnesium oxide is the cheapest and most common form. It has the highest elemental magnesium content by weight (~60%), which is why labels can print impressive-looking numbers like “500mg” or “400mg.” But it absorbs the worst — roughly 4% fractional absorption (Firoz & Graber, 2001) — because it must fully dissociate in stomach acid before the body can use any of it, and much of the dose simply passes through unabsorbed. This unabsorbed magnesium draws water into the intestine, which is why oxide is a well-known laxative — not a well-known nutrient source.

Magnesium bisglycinate (also called magnesium glycinate) works through a fundamentally different mechanism. The magnesium is chelated — chemically bonded — to two molecules of the amino acid glycine. This chelate is absorbed through amino acid transport pathways in the intestinal wall, a dedicated system the body uses to absorb protein fragments. It bypasses the stomach-acid-dissociation bottleneck that limits oxide entirely. The result: meaningfully more magnesium reaches the bloodstream, with meaningfully less GI disruption.

Magnesium citrate sits in the middle. It dissolves more readily than oxide and absorbs moderately well, but the citric acid carrier draws water into the intestine — producing a milder but still significant laxative effect at the 300-400mg elemental doses commonly recommended for therapeutic use. Citrate is the form most often used in clinical laxative preparations, which tells you something about its intestinal behaviour at meaningful doses.

The head-to-head evidence — less than half the dose, substantially more absorption

The strongest quantified evidence for why form matters more than dose comes from a 2019 human bioavailability study by Blancquaert et al. (published in Nutrients). The researchers first tested 15 commercially available magnesium products in a validated gut simulator (SHIME), then carried the two products with the most opposing results forward to a head-to-head human trial.

The two products tested in humans: “Ultractive Magnesium” (196mg elemental Mg per tablet, a blend containing organic/chelated magnesium forms — the best in vitro performer) vs “B-Magnum” (450mg elemental Mg per tablet, pure magnesium oxide — the worst in vitro performer, and more than double the elemental magnesium of Ultractive).

This is not a mechanistic argument or a theoretical prediction. It is a direct, measured, statistically significant human result (p=0.009-0.011): less than half the elemental dose produced a substantially larger serum response, because the form it was delivered in allowed the intestine to actually absorb it. The full 450mg oxide dose produced a serum magnesium change indistinguishable from placebo-level circadian variation — as if no magnesium had been taken at all.

Doubling the organic-form dose (1→2 tablets, 196mg→392mg) did NOT produce a significantly higher serum response either — there was no simple linear dose-response once a well-absorbed form was used, reinforcing that solubility and formulation quality, not just elemental loading, is the limiting factor for how much magnesium your body actually receives.

Magnesium bisglycinate and sleep — the 2025 clinical evidence

A 2025 double-blind, placebo-controlled randomised trial (Schuster et al., published in Nature and Science of Sleep) enrolled 155 adults aged 18-65 with self-reported poor sleep quality. Participants received either 250mg elemental magnesium as bisglycinate daily or placebo for four weeks.

Result: the magnesium bisglycinate group showed a significantly greater reduction in Insomnia Severity Index (ISI) scores compared to placebo (−3.9 vs −2.3, p=0.049). The effect size was modest (Cohen’s d = 0.2), but the finding is significant because it is the first human RCT specifically demonstrating bisglycinate’s effect on sleep quality — not magnesium in general, but bisglycinate specifically. Exploratory analyses suggested notably greater improvements among participants with lower baseline dietary magnesium intake, meaning the effect was most pronounced in people whose gap was greatest.

This is consistent with what the absorption science predicts: bisglycinate gets more magnesium into the body than oxide or citrate, and magnesium supports nervous system relaxation and sleep through its role as a natural NMDA receptor modulator and its involvement in melatonin regulation. Additionally, the glycine component of bisglycinate has its own independently documented calming properties — glycine activates inhibitory receptors in the brainstem that contribute to sleep onset and quality.

The three forms compared — mechanism, absorption, tolerance

Check your own label — what to look for on your current supplement